SCHEDULE: BlackRock Discloses 6.1% Passive Stake in Solid Biosciences Inc.

BlackRock, Inc. has filed a Schedule 13G, revealing a 6.1% beneficial ownership stake in Solid Biosciences Inc.'s common stock as of June 30, 2025.

Summary

• BlackRock, Inc. reported beneficial ownership of 4,712,573 shares of Solid Biosciences Inc. common stock.
• This ownership represents 6.1% of the class of securities.
• BlackRock holds sole voting power over 4,595,024 shares and sole dispositive power over 4,712,573 shares.
• The filing indicates a passive investment, as the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
• The filing was made by BlackRock, Inc. and its Reporting Business Units, which include subsidiaries like BlackRock Advisors, LLC and BlackRock Fund Advisors.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership, providing neutral information without expressing positive or negative sentiment regarding the issuer's performance or outlook.

Positives

• BlackRock, a major institutional investor, holding a significant 6.1% stake in Solid Biosciences Inc. may signal confidence in the company's long-term prospects.
• The passive nature of the investment suggests BlackRock views the stake as a portfolio holding rather than an attempt to influence management, which can be seen as a stable investment.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding Solid Biosciences Inc.'s future performance or BlackRock's future investment intentions beyond the current beneficial ownership disclosure.

Industry Context

This filing reflects a standard disclosure by a large asset manager, BlackRock, Inc., regarding its significant passive investment in a publicly traded biotechnology company, Solid Biosciences Inc. Such disclosures are common for institutional investors crossing specific ownership thresholds and provide transparency into major holdings within various sectors.

Stakeholder Impact

• Shareholders of Solid Biosciences Inc. may view BlackRock's significant stake as a positive signal of institutional confidence in the company.
• The disclosure provides transparency to the market regarding a major institutional investor's position in the company.

Key Dates

Keywords

BlackRock, Solid Biosciences Inc., Schedule 13G, beneficial ownership, institutional investment, common stock, passive stake, asset management